Real-World Treatment Patterns in Patients with Advanced (Stage III–IV) Ovarian Cancer in the USA and Europe

Abstract

Aim: To analyze real-world data relating to treatment decision-making in stage III–IV ovarian cancer (OC). Materials &methods: Real world data were collected from a survey of physicians and their patients (n = 2413) across Europe and the USA in 2017–2018. Results: 49% had stage IVb disease. 39, 54 and 7% of patients received first-line (1L), second-line, or 7% third-line or later treatment. In the 1L (ongoing or completed), 93% received platinum-containing regimens, 26% bevacizumab-containing regimens and 1% a PARP inhibitor-containing regimen. In 1L maintenance treatment, 81% received bevacizumab, 17% platinum-containing treatments and 6% a PARP inhibitor. Conclusion: The most common 1L treatment for advanced ovarian cancer was platinum-containing chemotherapy. Of those receiving 1L maintenance therapy, 70–99% (across countries) received targeted therapy.

Keywords: :

• advanced ovarian cancer
• maintenance
• real-world evidence
• survey
• treatment

Author contributions

All authors contributed to conception and design, were involved in drafting the manuscript and revising it for critically important intellectual content, have given final approval of the version to be published and agree to be accountable for all aspects of the work.

Financial & competing interests disclosure

This trial was sponsored by Pfizer and is part of an alliance between Pfizer and Merck KGaA, Darmstadt, Germany. Data collection was undertaken by Adelphi Real World as part of an independent survey sponsored by multiple pharmaceutical companies, one of which was Pfizer Inc. Pfizer did not influence the original survey through either contribution to the design of the questionnaires or data collection. The analysis described here was funded by Pfizer. J Chang and JC Cappelleri are employees and stockholders of Pfizer Inc. (which funded this study). JP Doherty was an employee of Pfizer Inc. at the time of this research. JP Hall, R Moon and O Higson are employees of Adelphi Real World. K Byrne was employed by Adelphi Real World at the time the work was undertaken. Adelphi Real World was a paid consultant to Pfizer in connection with the development of this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Medical writing support under the guidance of the authors was provided by C Evans, on behalf of Adelphi Real World, and was funded by Pfizer Inc, in accordance with Good Publication Practice (GPP3) guidelines [40].

Additional information

Funding

This trial was sponsored by Pfizer and is part of an alliance between Pfizer and Merck KGaA, Darmstadt, Germany. Data collection was undertaken by Adelphi Real World as part of an independent survey sponsored by multiple pharmaceutical companies, one of which was Pfizer Inc. Pfizer did not influence the original survey through either contribution to the design of the questionnaires or data collection. The analysis described here was funded by Pfizer. J Chang and JC Cappelleri are employees and stockholders of Pfizer Inc. (which funded this study). JP Doherty was an employee of Pfizer Inc. at the time of this research. JP Hall, R Moon and O Higson are employees of Adelphi Real World. K Byrne was employed by Adelphi Real World at the time the work was undertaken. Adelphi Real World was a paid consultant to Pfizer in connection with the development of this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.